“Luspatercept: a lifesaving therapy for transfusion-dependent thalassemia patients with alloimmunization complications”

This case demonstrates the benefits of luspatercept for thalassemic patients who are unable to receive adequate blood transfusions. It acts as a selective ligand trap and inhibits TGF- signaling via Smad2/3 promote differentiation maturation late-stage erythroid precursors. Phase III clinical data showed that 33% reduction in transfusion burden from baseline was achieved. The administration challenge due coexistence antiphospholipid syndrome, portal vein thrombosis splenectomy. Since initiating luspatercept, patient has not experienced any adverse events her general condition improved.